| Safe, nontoxic, highly stable, cost effective |
Safe and viable therapeutic goal |
| Easily manufactured/synthesized/characterized |
Effective blocking signaling pathways |
| Epitopes are easily identified and predicted |
High affinity, selectivity and potency |
| Break tumor tolerance |
Retro-inverso D-amino acid peptides are stable |
| No oncogenic material included and minimal toxicity |
Reduces off-target side effects |
| Administered by simple routes s.c, im injections |
Large number of peptide-based drugs being marketed |
| Multi-epitope approach leads to broad antigen recognition and universal coverage |
No accumulation in specific organs such as kidney and liver minimizing side-effects |
| High affinity, high specificity, strong potency and improved safety profiles |
Increased bioavailability in vivo
|
| Booster vaccinations |
Water soluble, non-immunogenic, low cost production, enhanced shelf life and to easily cross tissue barriers |
| Elicits B and T cell memory responses |
MHC class I & II T cell epitopes easily identified |
| Sustainable production of antibodies in vivo
|
Induction of effective CD8 or CD4 T cell responses in vivo by targeting immune checkpoint blockade |
| Clinical grade peptides easily synthesized for rapid translation into Phase I/II clinical trials |
Easy monitoring of T cell responses |
